Schuler-Thurner et al. Vol. 195, No. 10, May 20, 2002. Pages 1279–1288.

The authors regret that a footnote was missing in Table I. The footnote is for Intestine D under the Others heading. The corrected table appears below.

Table I.

Patient́s Characteristics, Status Before and Response to DC Vaccination










Metastases at study entry






Regional
Distant

Patientcode
Sexage
Center
Previoustherapy
Skin
LN
Skin
LN
Lung
Liver
Skeleton
Others
Clinicalresponse
Fully evaluable patients (five vaccinations)             
02 m-48 S, ILP, IT, RT, CIT D/5 Pancreas 2/35 CR 
05 f-77 S, ILP, IT, RT, CT 6/34  SD 
08 f-64 S, IT, CIT, CT 1/3 1/4 2/80 Muscle 1/60 OP 
10 m-41 S, IT 2/13  SD 
12 f-65 S, CT 1/15 D/10  SD 
14 m-58 S, IT, CT D/25  OP 
15 f-35 S, CIT 2/20  SD 
16 m-63 2/30 1/25 1/20  OP 
17 f-60 S, CIT D/10 3/26 1/3  Kidney 2/15, suprarenal 2/60 OP 
18 m-77 3/30 1/14 3/60  OP 
19 m-70 S, IT 9/25 2/25  OP 
20 m-64 S, IT, RT D (>50)/5 D/5  SD 
21 m-59 S, IT 2/9  SD 
23 f-36 S, IT, CT 3/14 Intestine Da SD 
27 f-44 S, IT 1/51 1/16  SD 
28 m-55 S, CIT, ILP 2/6 3/30  OP 
Not fully evaluable patients (less than five vaccinations)             
01 f-29 CIT D/8 1/5 Spleen 3/35 peritoneum D muscle 2/30  
03 m-59 S, IT, CT 1/70 D/15 Sinus cavernosus infiltration; bone  
04 f-55 S, IT, CT  D/30  OP 
07 f-48 S, CIT, RT 1/20 D/50  OP 
09 m-57 S, CIT 1/11 Pancreas, duodenum, gastric D OP 
11 f-71 D (>50)/5   OP 
13 f-49 D/35  OP 
24
 
f-37
 
I
 
S, CT, IT, RT
 
-
 
-
 
-
 
1/45
 
1/20
 
-
 
-
 

 
OP
 









Metastases at study entry






Regional
Distant

Patientcode
Sexage
Center
Previoustherapy
Skin
LN
Skin
LN
Lung
Liver
Skeleton
Others
Clinicalresponse
Fully evaluable patients (five vaccinations)             
02 m-48 S, ILP, IT, RT, CIT D/5 Pancreas 2/35 CR 
05 f-77 S, ILP, IT, RT, CT 6/34  SD 
08 f-64 S, IT, CIT, CT 1/3 1/4 2/80 Muscle 1/60 OP 
10 m-41 S, IT 2/13  SD 
12 f-65 S, CT 1/15 D/10  SD 
14 m-58 S, IT, CT D/25  OP 
15 f-35 S, CIT 2/20  SD 
16 m-63 2/30 1/25 1/20  OP 
17 f-60 S, CIT D/10 3/26 1/3  Kidney 2/15, suprarenal 2/60 OP 
18 m-77 3/30 1/14 3/60  OP 
19 m-70 S, IT 9/25 2/25  OP 
20 m-64 S, IT, RT D (>50)/5 D/5  SD 
21 m-59 S, IT 2/9  SD 
23 f-36 S, IT, CT 3/14 Intestine Da SD 
27 f-44 S, IT 1/51 1/16  SD 
28 m-55 S, CIT, ILP 2/6 3/30  OP 
Not fully evaluable patients (less than five vaccinations)             
01 f-29 CIT D/8 1/5 Spleen 3/35 peritoneum D muscle 2/30  
03 m-59 S, IT, CT 1/70 D/15 Sinus cavernosus infiltration; bone  
04 f-55 S, IT, CT  D/30  OP 
07 f-48 S, CIT, RT 1/20 D/50  OP 
09 m-57 S, CIT 1/11 Pancreas, duodenum, gastric D OP 
11 f-71 D (>50)/5   OP 
13 f-49 D/35  OP 
24
 
f-37
 
I
 
S, CT, IT, RT
 
-
 
-
 
-
 
1/45
 
1/20
 
-
 
-
 

 
OP
 

Deceased.

a

Surgically removed prior to therapy.

Treatment Centers: E, Erlangen; I, Innsbruck.

Pretreatment therapy: IT, immunotherapy; C(I)T, chemo(immuno)therapy; S, surgery.

RT, radiotherapy; ILP, isolated limb perfusion.

Metastases at study entry: the number and diameter of the largest metastases present at study entry are listed (number/diameter in mm); D, diffuse.

Clinical Response: CR, complete regression; OP, overall progression; SD, stable disease.